⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8519198 | 0.70 | — | — | |
| SCHEMBL6155448 | 0.70 | — | — | |
| SCHEMBL3079391 | 0.60 | GRIN2D (0.42) | — | |
| SCHEMBL25422727 | 0.57 | GRIN2D (0.35) | — | |
| SCHEMBL8397281 | 0.54 | GRIN2D (0.50) | — | |
| SCHEMBL3872262 | 0.53 | GRIN2D (0.33) | — | |
| SCHEMBL8583485 | 0.53 | KDM4E (0.33) | — | |
| SCHEMBL25422729 | 0.51 | CYP2C9 (0.30) | — | |
| SCHEMBL8843172 | 0.51 | GRIN2D (0.35) | — | |
| SCHEMBL3065689 | 0.49 | SIGMAR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | disclosed |